Abstracts Archive - Page 583 of 2607 - ACR Meeting Abstracts

Abstract Number: 1491 • ACR Convergence 2022
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
David Kiefer¹, Juergen Braun¹, Lucia Schneider¹, Niklas Kolle¹, Uta Kiltz¹, Ioana Andreica², Philipp Sewerin¹, Bjoern Buehring³, susanne herbold¹ and Xenofon Baraliakos⁴, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Bergisches Rheuma-Zentrum, Velbert, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
Abstract Number: 1503 • ACR Convergence 2022
Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Rosalinde Stal⁴, Xenofon Baraliakos⁵, Juergen Braun⁶, Monique Reijnierse⁴, Caroline Bastiaenen⁷, Sofia Ramiro⁴ and floris van Gaalen⁴, ¹Leiden University Medical Center, Coimbra, Portugal, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Department of Epidemiology, Maastricht University, Maastricht, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), inflammation-driven trabecular bone loss is hypothesised to trigger bone repair at an anatomically distinct site of the same vertebra…
Abstract Number: 1504 • ACR Convergence 2022
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
Alexis Ogdie¹, Christopher Ritchlin², Priscila Nakasato³, Ran Liu⁴, Christian Kaufmann⁴, Byron Padilla⁵ and Laure Gossec⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³AbbVie Inc, Toronto, ON, Canada, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶Sorbonne Université, Paris, France
Background/Purpose: PsA is a systemic disease involving multiple domains. Peripheral joints are frequently affected, and patients often initially present with asymmetrical oligoarthritis (2-4 swollen joints).…
Abstract Number: 1494 • ACR Convergence 2022
Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years
Faten Hamitouche¹, Sushmitha Kumaradev¹, Désirée van der Heijde², Sofia Ramiro³, Alexandre Sepriano⁴ and Anna Molto⁵, ¹INSERM U-1153, Université Paris-Cité, CRESS, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Centre, Portela Loures, Portugal, ⁵Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France
Background/Purpose: A definition for clinically important worsening (CIW) of axial Spondyloarthritis (axSpA) has been proposed by ASAS: i.e. an increase of ≥0.9 points of ASDAS.…
Abstract Number: 1502 • ACR Convergence 2022
Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
Evan Siegel¹, Amit Garg², Jeffrey Carter³, Laura Simone⁴ and Marykate Nelson⁵, ¹Georgetown University School of Medicine, Washington, DC, ²Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, ³PRIME Education, Boynton Beach, FL, ⁴PRIME Education, Omaha, NE, ⁵PRIME Education, Drexel Hill, PA
Background/Purpose: The optimal care of psoriatic arthritis (PsA) requires effective collaboration between rheumatology and dermatology teams. We executed an initiative to identify gaps and inform…
Abstract Number: 1515 • ACR Convergence 2022
Assessing the Difference Between Radiographic Axial Spondylorthritis and Non-radiographic Axial Spondylorthritis in a Two-center Descriptive Study with Mexican Patients: The Influence of Clinical, Demographic, Laboratory and Clinimetric Features
John Londono¹, Gustavo Rodriguez-Salas², Igor Rueda-Cardenas³, Ana Maria Santos¹, Marta Mantilla¹, Juan Camilo Santacruz², Cesar Pachecho⁴, Gilberto Vargas-Alarcon⁵ and Ruben Burgos vargas⁶, ¹Spondyloarthropathies study group - Universidad de La Sabana - Hospital Militar Central, Bogotá, Colombia, ²Spondyloathropathies study group Universidad de La Sabana Hospital Militar Central, Bogotá, Colombia, ³Spondyloarthropathies study group - Universidad de LA Sabana - Hospital Militar Central, Colombia, Colombia, ⁴Universidad Autónoma de chihuahua, Chihuahua, Mexico, ⁵Insituto Nacional de Cardiología Ignacio Chavez, Ciudad de México, Mexico, ⁶hospital general de mexico, Ciudad de México, Mexico
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases that have some key features in common. According to ASAS, this condition is classified into…
Abstract Number: 1509 • ACR Convergence 2022
Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations
Xenofon Baraliakos¹, Effie Pournara², Dafna Gladman³, Philip J Mease⁴, Samad S Jahandideh² and Laura Coates⁵, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Universally acceptable clinical and imaging criteria to define axial psoriatic arthritis (PsA) is lacking.1 Machine learning (ML) algorithms can detect patterns from large clinical…
Abstract Number: 1511 • ACR Convergence 2022
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
Dafna Gladman¹, Ghaydaa Aldabie², Fangya Ma³, Mitchell Sutton⁴, Ker-Ai Lee³ and Richard Cook³, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³University of Waterloo, Waterloo, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The majority of patients with PsA present with skin manifestations first. Several studies have examined the relationship between activity/severity of skin and joint manifestations,…
Abstract Number: 1507 • ACR Convergence 2022
Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
Neel Tapryal¹, George Gondo², M. Elaine Husni³, Alice Gottlieb⁴ and Joseph Merola⁵, ¹Cleveland Clinic, Rocky River, OH, ²National Psoriasis Foundation, Portland, OR, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis in which the time between symptom onset and a diagnosis of PsA is highly variable.…
Abstract Number: 1518 • ACR Convergence 2022
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Ashima Makol¹, Alicia Hinze², Rachel Giblon¹, Yasser Radwan³, Tina Gunderson⁴, David Liedl¹, Kenneth J. Warrington⁴, Cynthia Crowson⁵ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic/ Michigan State University, Lansing, MI, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Digital ischemic complications (DICs, including digital ulcers, digital pitting/scars, gangrene and/or amputation) can significantly impact hand function, disability and overall prognosis in SSc. We…
Abstract Number: 1517 • ACR Convergence 2022
Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain
Nelly Ziade¹, Avin Maroof², Antonella Abi Najm¹, Torsten Witte³ and Xenofon Baraliakos⁴, ¹Saint-Joseph University, Beirut, Lebanon, ²Rizgary Teaching Hospital - Erbil, Erbil, Iraq, ³MH-Hannover, Hannover, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) are diagnosed late, partially due to the absence of a reliable biomarker. The diagnostic value of the anti-CD74 antibodies…
Abstract Number: 1519 • ACR Convergence 2022
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Erin Chew¹, Sarah Wood¹, Bibin Varghese¹, Christopher Chew², erin wilfong¹ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Primary heart involvement in systemic sclerosis (SSc-pHI) is characterized by myocardial inflammation with resultant fibrosis that is not secondary to ischemic heart disease or…
Abstract Number: 1461 • ACR Convergence 2022
The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis
Omer Pamuk¹ and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus…
Abstract Number: 1410 • ACR Convergence 2022
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Ricardo Blanco⁴, Miguel Angel Gonzalez Gay⁵ and Alfonso Corrales⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Lugo, Spain, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
Abstract Number: 1266 • ACR Convergence 2022
Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission
Takehisa Ogura¹, Takaharu Katagiri², Yuto Takakura³, Chihiro Imaizumi⁴ and Hideto Kameda⁴, ¹Toho university, Meguro-ku, Japan, ²Toho University School of Medicine (Ohashi Medical Center), Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ³Toho University, Setagayaku, Japan, ⁴Toho University, Tokyo, Japan
Background/Purpose: Ultrasonography (US) has been suggested to be useful in predicting flare in patients with rheumatoid arthritis (RA) after discontinuation of biological disease-modifying antirheumatic drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].